![Lipella Pharmaceuticals Inc](/common/images/company/N_LIPO.png)
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinic... Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania. 詳細を表示
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.57 | -14.0049140049 | 4.07 | 4.5 | 3.43 | 522774 | 4.21993049 | CS |
4 | 0.63 | 21.9512195122 | 2.87 | 7.31 | 2.5 | 7320841 | 4.50774779 | CS |
12 | 0.7 | 25 | 2.8 | 7.31 | 2.5 | 2571717 | 4.45918165 | CS |
26 | 0.172 | 5.16826923077 | 3.328 | 7.31 | 2.21 | 1688002 | 4.1137718 | CS |
52 | -4.5 | -56.25 | 8 | 12 | 2.21 | 1691952 | 5.62146952 | CS |
156 | -52.66 | -93.7678062678 | 56.16 | 61.76 | 2.21 | 989935 | 8.7654027 | CS |
260 | -52.66 | -93.7678062678 | 56.16 | 61.76 | 2.21 | 989935 | 8.7654027 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約